Annexon Inc is a pioneering biopharmaceutical firm focused on developing treatments for autoimmune, neurodegenerative, and eye diseases. Leveraging its expertise in the classical complement pathway, particularly the C1q molecule, Annexon is advancing a portfolio of therapies aimed at addressing complex conditions like Guillain-Barré syndrome, Huntington's disease, and lupus nephritis. With its lead candidates in various stages of clinical trials, including monoclonal antibodies and oral small molecules, Annexon is at the forefront of targeting diseases with significant unmet medical needs. Founded in 2011, the company is based in Brisbane, California.
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
